New hope for Tough-to-Treat bone cancer in kids and young adults
NCT ID NCT05830084
Summary
This study is testing if it's safe to add a drug called regorafenib to the standard, intensive chemotherapy for Ewing sarcoma. It aims to help children and young adults (ages 2-49) whose cancer has spread to multiple parts of the body, a situation with very limited treatment options. The main goal is to find the right dose of regorafenib that can be given alongside chemo without causing severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Bordeaux
Bordeaux, France
-
Centre Oscar Lambret
Lille, France
-
Gustave Roussy
Villejuif, Île-de-France Region, 94805, France
-
Institut Curie
Paris, France
-
Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Monash Children's Hospital
Clayton, Australia
-
Perth Children's Hospital
Perth, WA6009, Australia
-
Princess Máxima Center
Utrecht, 113, Netherlands
-
Queensland Children's Hospital
Brisbane, Australia
-
Rigshospitalet
Copenhagen, DK-2100, Denmark
-
Royal Children's Hospital
Parkville, Australia
-
Vall d'Hebron University Hospital
Barcelona, 119-12, Spain
-
centre Léon Bérard
Lyon, France
Conditions
Explore the condition pages connected to this study.